High Levels of Serum Bile Acids in COVID-19 Patients on Hospital Admission

INTRODUCTION Bile acids are signaling molecules with immune, metabolic and intestinal microbiota control actions. In high serum concentrations they increase inﬂ ammatory response from the liver-gut axis, until causing multiorgan failure and death; therefore, they may be associated with COVID-19’s clinical progression, as a consequence of tissue and metabolic damage caused by SARS-CoV-2. While this topic is of considerable clinical interest, to our knowledge, it has not been studied in Cuba. OBJECTIVE Study and preliminarily characterize patients admitted with a diagnosis of COVID-19 and high levels of serum bile acids. METHODS A preliminary exploratory study was carried out with descriptive statistical techniques in 28 COVID-19 patients (17 women, 11 men; aged 19–92 years) who exhibited high levels of serum bile acids (≥10.1 μmol/L) on admission to the Dr. Luis Díaz Soto Central Military Hospital in Havana, Cuba, from September through November 2021. RESULTS On admission patients presented hypocholes-terolemia (13/28; 46.4%), hyperglycemia (12/28; 43.0%) and hyper gamma-glutamyl transpeptidase (23/28; 84.2%). Median blood glucose (5.8 mmol/L) and cholesterol (4.1 mmol/L) were within normal ranges (3.2‒6.2 mmol/L and 3.9‒5.2 mmol/L, respectively). Severe or critical stage was the most frequent (13/28) and median serum bile acids (31.6 μmol/L) and gamma-glutamyl transferase (108.6 U/L) averaged well above their respective normal ranges (serum bile acids: 0‒10 μmol/L; GGT: 9‒36 U/L). Arterial hypertension was the most frequent comorbidity (19/28; 67.9%). CONCLUSIONS Severe or critical stage predominated, with serum bile acids and gamma-glutamyl transferase blood levels above normal ranges. The study suggests that serum bile acid is toxic at levels ≥10.1 μmol/L, and at such levels is involved in the inﬂ ammatory process and in progression to severe and critical clinical stages of the disease. In turn, this indicates the importance of monitoring bile acid homeostasis in hospitalized COVID-19 patients and including control of its toxicity in treatment protocols.


INTRODUCTION
Toxic action of bile acids has been reported since 1933 and their biological activities were described in the late 1990s.Bile acids are signaling molecules and, when interacting with nuclear receptors and cellular transporters, express a sequence of actions linked to physical-chemical properties, conjugation with glycine or taurine, primary or secondary synthesis, and hepatic and intestinal transport, among others.[1,2] These properties explain their pleiotropic activities, such as intestinal absorption of fats and fat-soluble vitamins, and control of energy, lipid, glycemic, cholesterol and immune-system metabolism.This would also explain their infl uence on the specifi c activity of organs such as the heart, lungs, kidneys and nervous system.[3,4] These concepts off er a comprehensive view of their biological activities within the framework of novel approaches in human physiology.[5] In vivo and in vitro studies show that high levels of bile acids maintained on plasma membranes and cellular DNA generate an infl ammatory sequence that increases oxidative stress, protein denaturation and misfolding, decreased calcium and iron ion levels, and formation of secondary structures in DNA, as well as dysfunction of mitochondria and other organelles, responsible for genesis and persistence or amplifi cation of the infl ammatory and proinfl ammatory response.[5,6] Reference levels considered normal vary according to the different assays and units of measurement used, and may be standardized internationally, regionally, and even by institutions and reagent manufacturers.Thus, the normal range used by the International System of Units (SI) is 10-19 μmol/L, [7] Chinese researchers use 0-12 μmol/L, [8] while the German company DiaSys Diagnostic Systems (GmbH) uses a normal range of 0-10 μmol/L.[9] Despite reports of digestive and extradigestive toxic eff ects of serum bile acids and use of new therapeutic interventions, such as ursodeoxycholic acid in various conditions and in pregnancy, [10] there has IMPORTANCE This is the fi rst report in Cuba of COVID-19 cases with high levels of serum bile acids on hospital admission.Its fi ndings suggest disease progression could be linked to the toxic eff ect of bile acids, such as worsening of the clinical stage and high levels of gamma-glutamyl transferase.The study establishes several premises for further research related to serum bile acids in management and follow-up of COVID-19 patients.

COVID-19 Case Study Peer Reviewed
Peer Reviewed been virtually no published research on serum levels in COVID-19, the results of which could explain clinical and tissue changes in patients, conditioned by homeostatic decontrol of bile acids.This is the fi rst report in Cuba of cases with COVID-19 and high serum levels of bile acids (≥10.1 μmol/L) and it aims to describe characteristics of patients on admission, as a fi rst step to considering eventual changes in clinical teaching, care and research regarding this potential association.

METHODS
A case study was conducted for reasons of feasibility, its fl exible design enabling a preliminary approach to the problem, hypothesis generation and formulation of bases for future studies.
The Dr. Luis Díaz Soto Central Military Hospital is a general hospital that also serves the adjacent civilian population and has a gynecology-obstetrics service.In the pandemic, this Havana facility also received all pregnant COVID-19 confi rmed cases in the city.[11] During September-November 2021, 91 PCR-confi rmed COVID-19 patients were admitted.On admission, all patients underwent serum bile acid assay, found to be high in 28 patients who comprised the case series studied; all were aged >18 years, and the group included six pregnant and two postpartum women.
Patients were interviewed; physical exams, imaging studies and blood tests were carried out.

Study variables
Evaluated were: clinical stage (mild: patient with mild symptoms, such as upper respiratory symptoms, no pneumonia; moderate: patient with mild pneumonia without respiratory failure or infl ammatory response; severe: patient presenting pneumonia with acute respiratory failure, and pneumonia with infl ammation and hypercoagulability; critical: patient with intubation and assisted ventilation, shock and multiorgan failure), [11] clinical and imaging assessment, blood tests (blood glucose, cholesterol, gamma-glutamyl transferase or GGT, and serum bile acids) and comorbidities.
Bile acid testing at admission was done using a stand-alone clinical chemistry analyzer (Cobas c 311, Roche Diagnostics International Ltd, Switzerland) that fulfi lled parameters for calibration and calculation stability with standards in μmol/L established by DiaSys Diagnostic Systems GmbH (Germany), which consider reference values of 0-10 μmol/L as normal and ≥10.1 μmol/L as high.[9] For blood glucose, cholesterol and GGT, methods standardized in Cuba's clinical laboratories and approved by the country's Ministry of Public Health were used.[12] Results were presented in frequency tables.

Ethics
This study followed the principles of the Declaration of Helsinki.[13] Patients or legal guardians (in cases of critical and disabled patients) provided written informed consent and patient anonymity was maintained.

RESULTS
Table 1 shows the results of the case series.Of the total admitted cases, 30.8% (28/91) had high serum bile acids at admission.Ages ranged from 19 to 92 years, and 60.7% of cases (17/28) were women.The series had a mean serum bile acid of 23.9 μmol/L, with a median of 28.7 μmol/L.Values were higher the more severe the clinical picture (Table 2).GGT fi gures were the furthest from the normal range, with a median of 76.5 U/L, higher in patients at the severe or critical stages (108.0U/L).All cases had a clinical and imaging diagnosis of pneumonia or bronchopneumonia on admission.There was a remarkable abundance of comorbidities.

DISCUSSION
High rates of mortality, morbidity and sequelae from COVID-19 are related to immune and metabolic disorders that are the pathophysiological basis of the disease.[14] These disorders involve the release of multiple proinfl ammatory mediators that trigger an infl ammatory response in various organs and tissues.These tissues contain angiotensin-converting enzyme 2 (ACE2) receptors, used by SARS-CoV-2 for cell entry.Once inside the cell, the viral particles cause damage that results in immune intolerance and metabolic dysregulation in general, especially of cholesterol.
It should be noted that 50% of derivatives of the end product of hepatic cholesterol catabolism are bile acids.[15] When SARS-CoV-2 infects susceptible cells in various organs, especially those of the cholangiolar epithelium (cholangiocytes) of the bile canaliculi and bile ducts, it triggers an infl ammatory response that results in functional damage and lysis, which impacts bile acid secretion and transport.[16] The epithelial cells of the terminal ileum have the second highest distribution of ACE2 receptors in the body.Upon infection, the absorption, intestinal microbiota and intracellular transport of bile acids are dysregulated.[17] In severe and critical COVID-19 patients, clinical manifestations of intestinal failure have been observed, presenting as uncontrolled metabolic homeostasis and proinfl ammatory mediators released by immune system cells.There is also uncontrolled intestinal motility, mucus secretion and breakdown of the intestinal barrier.This infl ammatory process can lead to alterations in intestinal permeability, bacterial translocation, local or systemic sepsis and in extreme cases multiorgan failure and death.Bile acids may infl u-ence or be one of the factors that trigger the process.[18] However, there is a notable absence of reports in the medical literature of patients with COVID-19 whose clinical manifestations (cardiac, renal, pulmonary, hematological, neurological and intestinal) are associated with homeostatic imbalance of bile acids or evidence of the toxic damage they cause.[2,4] Furthermore, bile acids are neither part of the optional or required blood chemistry in care of COVID-19 patients on admission nor throughout their disease, whether severe or critical.These tests are not included in the followup of patients in intensive care, or in any of the existing national [11] and international protocols, [19] despite all the accumulated evidence of their eff ect on other diseases that progress to severity and of their importance in the management of pregnancy with cholestasis or fatty liver.
This study has limitations inherent to exploratory designs based on case series, whose purpose is to describe potential clinically relevant fi ndings while not aspiring to signal causal relationships or other types of associations.Nevertheless, these preliminary results suggest the need to design and execute analytical studies that will enable a deeper understanding of the probable role of bile acids in the clinical course of patients with COVID-19.

CONCLUSIONS
The patients admitted with COVID-19 and high serum levels of bile acids levels in this case series were primarily women in the severe or critical stage, with GGT above normal for established ranges.
Coupled with the scarce evidence from recent literature, the study suggests at least two considerations: (1) that serum bile acid levels ≥10.1 μmol/L are toxic and are involved in the infl ammatory process and in disease progression to unfavorable clinical stages, and (2) that it is important to monitor bile acid homeostasis in hospitalized COVID-19 patients, and to include control of its toxicity in treatment protocols.

ACKNOWLEDGMENTS
The authors would like to thank DiaSys Diagnostic Systems GmbH (Germany), Dr Klaus E. Mönkemüller and Dr Enrique Abraham Marcel, suppliers of the diagnostic kits for measuring serum bile acids; Dr Jacinta Otero Iglesias, medical biostatistician, who contributed to the methodological design of the research; Ivet López Rodríguez, representative of the Embassy of the Republic of Cuba in Germany, who helped arrange transportation of the diagnostic kits to Cuba; and to the medical staff of the Dr Luis Díaz Soto Central Military Hospital, for caring for the patients and gathering their information.